Skip to content

Visionary Ventures

Venture capital fund investing life sciences focusing in ophthalmology medical devices and pharmaceuticals.

HOME
OPHTHALMOLOGY FUND
Visionary KOLs
TEAM
- Investment Committee
- Fund Management
PORTFOLIO
NEWS
CONTACT
INVESTOR LOGIN

Fund Menu

Search:

HOME
OPHTHALMOLOGY FUND
Visionary KOLs
TEAM
- Investment Committee
- Fund Management
PORTFOLIO
NEWS
CONTACT
INVESTOR LOGIN

Dr. Bob Avery

International lecturer on retinal diseases. Founder of the California Retina Research Foundation

Search:

Recent Posts

AURION BIOTECH ANNOUNCES FIRST SUBJECT DOSED IN U.S. PHASE 1 / 2 CLINICAL TRIAL
October 25, 2023
ORASIS PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF QLOSI™ (PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION) 0.4% FOR THE TREATMENT OF PRESBYOPIA
October 18, 2023
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
August 28, 2023

Categories

Acquisition(2)
Aurion(4)
IanTECH(2)
Iantrek(1)
IPO(2)
License Deal(1)
News(62)
ONL(2)
Orasis(16)
Re-Vana(4)
RxSight(2)
Surface(1)
Sydnexis(2)
Tarsus(7)
Tear Film(4)
TearClear(8)
Visionary(9)

Archives

Visionary Ventures is a venture capital fund that invests in life sciences and the future of ophthalmology. We are an opportunistic venture fund that invests in early and late stages of a company's growth, from early-stage Series A rounds in clinical trials to late-stage rounds in commercialization. Our target investment range is $5M to $15M.

Contact Us

Visionary Ventures
620 Newport Center Drive, Suite 650
Newport Beach CA 92660
info@visionaryvc.com

Home
Ophthalmology
Team
Portfolio
News
Contact
Investor Portal

Footer Menu

© 2019 Visionary Ventures. All Rights Reserved.